CENTRAL-NERVOUS-SYSTEM EFFECTS OF SUBDISSOCIATIVE DOSES OF (S)-KETAMINE ARE RELATED TO PLASMA AND BRAIN CONCENTRATIONS MEASURED WITH POSITRON EMISSION TOMOGRAPHY IN HEALTHY-VOLUNTEERS

被引:101
作者
HARTVIG, P
VALTYSSON, J
LINDNER, KJ
KRISTENSEN, J
KARLSTEN, R
GUSTAFSSON, LL
PERSSON, J
SVENSSON, JO
OYE, I
ANTONI, G
WESTERBERG, G
LANGSTROM, B
机构
[1] UNIV UPPSALA HOSP,DEPT ANESTHESIOL & INTENS CARE,S-75185 UPPSALA,SWEDEN
[2] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN PHARMACOL,S-75185 UPPSALA,SWEDEN
[3] UNIV OSLO,SCH MED,DEPT PHARMACOL,OSLO,NORWAY
关键词
D O I
10.1016/0009-9236(95)90194-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Plasma concentrations, maximum regional brain concentrations, and specific regional binding in the brain after administration of 0, 0.1, and 0.2 mg/kg doses of (S)-ketamine were measured in a randomized, double-blind, crossover study in five volunteers and were related to induced effects such as analgesia, amnesia, and mood changes. Specific binding in the brain was assessed by simultaneous administration of (S)-[N-methyl-C-11]ketamine quantified by positron emission tomography. High radioactivities in the brain corresponded to regional distribution of N-methyl-D-aspartate receptor complexes. A significant and dose-dependent reduction of binding was measured as a result of displacement of (S)-[N-methyl-C-11]ketamine. Memory impairment and psychotomimetic effects were related to dose, plasma concentration 4 minutes after administration, and decreased regional binding of (S)-ketamine in the brain and were consistently seen at plasma and maximum regional brain (S)-ketamine concentrations higher than 70 and 500 ng/ml, respectively. The magnitude of specific binding of (S)-ketamine, measured with positron emission tomography, can be related directly to drug effects.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 22 条
[1]   CEREBRAL PHARMACODYNAMICS OF ANESTHETIC AND SUBANAESTHETIC DOSES OF KETAMINE IN THE NORMOVENTILATED PIG [J].
AKESON, J ;
BJORKMAN, S ;
MESSETER, K ;
ROSEN, I ;
HELFER, M .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1993, 37 (02) :211-218
[2]   KETAMINE AND MIDAZOLAM DECREASE CEREBRAL BLOOD-FLOW AND CONSEQUENTLY THEIR OWN RATE OF TRANSPORT TO THE BRAIN - AN APPLICATION OF MASS BALANCE PHARMACOKINETICS WITH A CHANGING REGIONAL BLOOD-FLOW [J].
BJORKMAN, S ;
AKESON, J ;
NILSSON, F ;
MESSETER, K ;
ROTH, B .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1992, 20 (06) :637-652
[3]  
COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61
[4]  
FERRARESE C, 1992, NEUROPHARMACOLOGY, V30, P899
[5]   BRAIN KINETICS OF (R)-[N-METHYL-C-11]KETAMINE AND (S)-[N-METHYL-C-11]KETAMINE IN THE RHESUS-MONKEY STUDIED BY POSITRON EMISSION TOMOGRAPHY (PET) [J].
HARTVIG, P ;
VALTYSSON, J ;
ANTONI, G ;
WESTERBERG, G ;
LANGSTROM, B ;
MOBERG, ER ;
OYE, I .
NUCLEAR MEDICINE AND BIOLOGY, 1994, 21 (07) :927-934
[6]   A PRELIMINARY EVALUATION OF THE SCANDITRONIX PC2048-15B BRAIN SCANNER [J].
HOLTE, S ;
ERIKSSON, L ;
DAHLBOM, M .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1989, 15 (11) :719-721
[7]   PERFORMANCE-CHARACTERISTICS OF AN 8-RING WHOLE-BODY PET SCANNER [J].
KOPS, ER ;
HERZOG, H ;
SCHMID, A ;
HOLTE, S ;
FEINENDEGEN, LE .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1990, 14 (03) :437-445
[8]   THE NMDA-RECEPTOR ANTAGONIST CPP ABOLISHES NEUROGENIC WIND-UP PAIN AFTER INTRATHECAL ADMINISTRATION IN HUMANS [J].
KRISTENSEN, JD ;
SVENSSON, B ;
GORDH, T .
PAIN, 1992, 51 (02) :249-253
[9]   SUBANESTHETIC EFFECTS OF THE NONCOMPETITIVE NMDA ANTAGONIST, KETAMINE, IN HUMANS - PSYCHOTOMIMETIC, PERCEPTUAL, COGNITIVE, AND NEUROENDOCRINE RESPONSES [J].
KRYSTAL, JH ;
KARPER, LP ;
SEIBYL, JP ;
FREEMAN, GK ;
DELANEY, R ;
BREMNER, JD ;
HENINGER, GR ;
BOWERS, MB ;
CHARNEY, DS .
ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) :199-214
[10]   NONCOMPETITIVE EXCITATORY AMINO-ACID RECEPTOR ANTAGONISTS [J].
LODGE, D ;
JOHNSON, KM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (02) :81-86